Biovica International AB Q1 2026 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Johan Unnerus - Redeye AB - Analyst : Thank you. Thank you for taking our questions. And can you hear me?

Question: Johan Unnerus - Redeye AB - Analyst : Excellent. So we'll start off with perhaps Tempus, you are improving clinical sales in the US fairly substantially in terms of percentages, but still from a modest absolute base and Tempus comes across as a quite significant opportunity given the sales force team and so on. So when can we expect the first sort of patient tested, and what's sort of left to get the Tempus team on the ground so to speak?

Question: Johan Unnerus - Redeye AB - Analyst : Yes. That's useful. So it sounds like it should be a sort of cautious uptick from that side or very limited in the current ongoing quarter. Is it possible to see some sales support already in Q3 in your

Question: Johan Unnerus - Redeye AB - Analyst : Yes. That's useful. And also, you used the term health care giant, and you have a study that will support some channels. When can we expect the study to start? You alluded to September, October. Is that realistic? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 11, 2025 / 12:00PM, BIOVICb.ST - Q1 2026 Biovica International AB Earnings Call

Question: Johan Unnerus - Redeye AB - Analyst : Yes. And that brings us to the next question, which relates to these additional resources. Is it a matter of sort of some specialist team input, or will it require external resources as is the case with studies?

Question: Johan Unnerus - Redeye AB - Analyst : Yes. And you also mentioned that you get better tractions and feedback from medical ad boards. And what do you do actively to promote that dynamic, and what will you do going forward?

Question: Johan Unnerus - Redeye AB - Analyst : And the opportunity to use DiviTum at an early stage of metastatic breast cancer, does that also capture some interest in this context of ad board medical?

Question: Johan Unnerus - Redeye AB - Analyst : And also, now when you get more sort of clinical feedback, it's obvious that genetic testing is gaining pace and there is probably a good case of combining DiviTum with genetic testing in different ways. Is that something you see or interest in, or have you got any comment on that?

Question: Johan Unnerus - Redeye AB - Analyst : And also, if I may, of course, tests that are sort of approved and start to gain traction, there is also a case that they would be including in some guidelines that can be done at various ways and status, so to speak. Is that something you're considering as well?

Question: Johan Unnerus - Redeye AB - Analyst : Tests like DiviTum and others are sometimes featured in the guidelines and that can be in different ways. Is that something you sort of see for DiviTum or. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 11, 2025 / 12:00PM, BIOVICb.ST - Q1 2026 Biovica International AB Earnings Call

Question: Johan Unnerus - Redeye AB - Analyst : Excellent. And finally, on the OpEx side, it's clearly reduced compared to Q1 last year. Could you elaborate on that and sort of the clean normal run rate? There are some extra costs. I think you changed the cost base last year for cost.

Question: Johan Unnerus - Redeye AB - Analyst : Excellent. Thank you. That's all for us. And sorry for all the questions, maybe it was too many.

Question: Johan Unnerus - Redeye AB - Analyst : Thank you.